Cargando…

Omicron breakthrough infections in patients with immune-mediated inflammatory diseases

Detalles Bibliográficos
Autores principales:	Liew, Jean W, Sattui, Sebastian E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398210/ https://www.ncbi.nlm.nih.gov/pubmed/36034739 http://dx.doi.org/10.1016/S2665-9913(22)00251-X

Ejemplares similares

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

Navigating use of rituximab during the COVID-19 pandemic
por: Elahee, Mehreen, et al.
Publicado: (2023)

Milder disease with Omicron: is it the virus or the pre-existing immunity?
por: Sigal, Alex
Publicado: (2022)

Immunosuppression and SARS-CoV-2 breakthrough infections
por: Kim, Alfred H J, et al.
Publicado: (2022)

Hospitalisation among vaccine breakthrough COVID-19 infections
por: Juthani, Prerak V, et al.
Publicado: (2021)

Severe breakthrough COVID-19 infections in Scotland—implications for immunisation programmes
por: Leshem, Eyal, et al.
Publicado: (2021)

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
por: Boekel, Laura, et al.
Publicado: (2022)

Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases
por: Sparks, Jeffrey A, et al.
Publicado: (2022)

Omicron infection milder in nursing home residents
por: Katz, Morgan J, et al.
Publicado: (2022)

Estimating disease severity of Omicron and Delta SARS-CoV-2 infections
por: Sigal, Alex, et al.
Publicado: (2022)

Lower risk of Multi-system inflammatory syndrome in children (MIS-C) with the omicron variant
por: Lopez, Laura, et al.
Publicado: (2022)

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2023)

Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease
por: Haberman, Rebecca H, et al.
Publicado: (2022)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

Omicron breakthrough infections in vaccinated or previously infected hamsters
por: Zhou, Jie, et al.
Publicado: (2023)

Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection
por: Lee, Wen Shi, et al.
Publicado: (2023)

Omicron severity: milder but not mild
por: Nealon, Joshua, et al.
Publicado: (2022)

Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4
por: Soto-Rifo, Ricardo
Publicado: (2023)

Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases
por: Goulenok, Tiphaine, et al.
Publicado: (2022)

Prioritisation of COVID-19 boosters in the omicron era
por: Irving, Stephanie A, et al.
Publicado: (2022)

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era
por: Boaventura, Viviane S, et al.
Publicado: (2023)

Omicron in pregnancy: time to breathe easier?
por: Auger, Nathalie, et al.
Publicado: (2022)

Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections
por: Möhlendick, Birte, et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City
por: Saxena, Amit, et al.
Publicado: (2022)

COVID-19 vaccination in patients with immunity-mediated kidney disease
por: Prendecki, Maria, et al.
Publicado: (2021)

Fixed cell-based assays for autoantibody detection in myasthenia gravis: a diagnostic breakthrough
por: Budhram, Adrian
Publicado: (2023)

Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults
por: Kared, Hassen, et al.
Publicado: (2022)

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
por: Sridhar, Saranya, et al.
Publicado: (2022)

Antibody titers and breakthrough infections with Omicron SARS-CoV-2
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Novel insights into the role of anti-inflammatory IL-38 in immunity against infection
por: Gao, Xun, et al.
Publicado: (2022)

Omicron: fewer adverse outcomes come with new dangers
por: Post, Lori Ann, et al.
Publicado: (2022)

SARS-CoV-2 spread and hospitalisations in paediatric patients during the omicron surge
por: Belay, Ermias D, et al.
Publicado: (2022)

1467. Breakthrough Omicron Infections in Booster Vaccinated Healthcare Workers
por: Lee, Jeongjae, et al.
Publicado: (2022)

New year, new SARS-CoV-2 variant: Resolutions on genomic surveillance protocols to face Omicron
por: Oróstica, Karen Y., et al.
Publicado: (2022)

IBD in the time of corona — vigilance for immune-mediated diseases
por: Moschen, Alexander R.
Publicado: (2020)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron Variant
por: Zhang, Yuwei, et al.
Publicado: (2023)

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5
por: Bormann, Maren, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4n04skqe1lacnen5ipqiir6ons